Table 1 Effects of antiretroviral combination therapy with nelfinavir, saquinavir, and two nucleoside analogues upon CSF and plasma HIV-1 RNA, CSF and serum neopterin, CSF and serum β2-microglobulin (β2 m), CSF monocytic cell count, CD4+ T- cell count, albumin ratio, and IgG index.
Baseline | Week 12 | Week 48 | |
|---|---|---|---|
CSF HIV-1 RNA (log10 copies/mL) | |||
Median (range) | 4.19 (2.20–5.40) | 1.54 (1.28–2.27) | 1.59 (1.28–3.10) |
No. of patients < 1.70 log10 copies/mL | 0/8 | 6/8 | 5/7 |
Plasma HIV-1 RNA (log10 copies/mL) | |||
Median (range) | 5.04 (3.85–5.58) | 1.60 (1.28–2.50) | 1.63 (1.28–5.29) |
No. of patients < 1.70 log10 copies/mL | 0/8 | 4/8 | 5/7 |
CSF neopterin (nmol/L) | |||
Median (range) | 25.5 (11.1–74.0) | 10.7 (6.5–25.6) | 7.0 (3.8–18.2) |
No. of patients = 4.3 nmol/L | 0/8 | 0/8 | 1/7 |
Serum neopterin (nmol/L) | |||
Median (range) | 16.4 (9.0–44.9) | 10.1 (6.0–22.3) | 7.0 (4.4–70.1) |
No. of patients = 8.8 nmol/L | 0/8 | 4/8 | 4/7 |
CSF β2 M (mg/L) | |||
Median (range) | 2.65 (1.10–7.10) | 1.40 (0.70–3.10) | 0.90 (0.50–1.60) |
No. of patients = 2.2 mg/L | 3/8 | 7/8 | 8/8 |
Serum β2 M (mg/L) | |||
Median (range) | 3.40 (1.70–4.50) | 2.40 (1.40–3.30) | 1.50 (1.30–4.30) |
No. of patients = 2.4 mg/L | 3/8 | 4/8 | 5/7 |
CSF monocytic cell count (x106/L) | |||
Median (range) | 11 (1–20) | 1 (0–7) | 1 (0–3) |
No. of patients = 4 × 106 cells/L | 3/7 | 7/8 | 7/7 |
CD4+ T-cell count (cells × 106/L) | |||
Median (range) | 200 (20–310) | 305 (100–390) | 330 (110–450) |
No. of patients = 200 cells × 106/L | 4/8 | 6/8 | 7/7 |
Albumin ratio | |||
Median (range) | 3.5 (2.1–10.8) | 3.2 (2.1–11.8) | 3.6 (1.8–3.8) |
No. of patients with normal values | 7/8 | 7/8 | 7/7 |
IgG index | |||
Median (range) | 0.98 (0.49–1.47) | 0.88 (0.57–2.24) | 0.70 (0.48–1.54) |
No. of patients < 0.63 | 1/8 | 1/8 | 2/7 |